AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes AbbVie, Alexandria Real Estate ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

Hold iShares U.S. Healthcare ETF (IYH): top holdings face GLP-1 risks, patent cliffs and high valuations. Read here for an ...

AbbVie Inc.’s founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday, and will be replaced by the company’s current president and chief operating officer, Robert Michael.

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...

Wednesday, January 14, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie ...

Biopharmaceutical company AbbVie has reached an agreement with the Trump administration to invest $100 billion in its U.S.